Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 3
2015 2
2016 2
2017 4
2018 4
2019 5
2020 5
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all Quoted phrase not found: "infection"
Page 1
A basic review on systemic treatment options in WHO grade II-III gliomas.
Mair MJ, Geurts M, van den Bent MJ, Berghoff AS. Mair MJ, et al. Among authors: geurts m. Cancer Treat Rev. 2021 Jan;92:102124. doi: 10.1016/j.ctrv.2020.102124. Epub 2020 Nov 13. Cancer Treat Rev. 2021. PMID: 33227622 Free article. Review.
WHO grade II-III gliomas are rare primary brain tumors occurring at a median age of about 35-55 years. Median survival is longer in WHO grade II-III glioma compared with WHO grade IV glioblastoma as survival times of up to 10 years and longer can be observed. ...The …
WHO grade II-III gliomas are rare primary brain tumors occurring at a median age of about 35-55 years. Median survival is longer in WHO grad …
Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives.
Weenink B, French PJ, Sillevis Smitt PAE, Debets R, Geurts M. Weenink B, et al. Among authors: geurts m. Cancers (Basel). 2020 Mar 22;12(3):751. doi: 10.3390/cancers12030751. Cancers (Basel). 2020. PMID: 32235752 Free PMC article.
In this perspective, we provide an overview of immune interventions performed to date in glioblastoma patients and re-evaluate their performance. We argue that shortcomings of current immune therapies in glioblastoma are related to three major determinants of resist …
In this perspective, we provide an overview of immune interventions performed to date in glioblastoma patients and re-evaluate their …
Adverse prognosis of glioblastoma contacting the subventricular zone: Biological correlates.
Berendsen S, van Bodegraven E, Seute T, Spliet WGM, Geurts M, Hendrikse J, Schoysman L, Huiszoon WB, Varkila M, Rouss S, Bell EH, Kroonen J, Chakravarti A, Bours V, Snijders TJ, Robe PA. Berendsen S, et al. Among authors: geurts m. PLoS One. 2019 Oct 11;14(10):e0222717. doi: 10.1371/journal.pone.0222717. eCollection 2019. PLoS One. 2019. PMID: 31603915 Free PMC article.
INTRODUCTION: The subventricular zone (SVZ) in the brain is associated with gliomagenesis and resistance to treatment in glioblastoma. In this study, we investigate the prognostic role and biological characteristics of subventricular zone (SVZ) involvement in glioblasto …
INTRODUCTION: The subventricular zone (SVZ) in the brain is associated with gliomagenesis and resistance to treatment in glioblastoma …
A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma.
Cui T, Bell EH, McElroy J, Liu K, Sebastian E, Johnson B, Gulati PM, Becker AP, Gray A, Geurts M, Subedi D, Yang L, Fleming JL, Meng W, Barnholtz-Sloan JS, Venere M, Wang QE, Robe PA, Haque SJ, Chakravarti A. Cui T, et al. Among authors: geurts m. Mol Cancer Res. 2021 Jan;19(1):48-60. doi: 10.1158/1541-7786.MCR-20-0353. Epub 2020 Sep 24. Mol Cancer Res. 2021. PMID: 32973101 Free article.
Rapid tumor growth, widespread brain-invasion, and therapeutic resistance critically contribute to glioblastoma (GBM) recurrence and dismal patient outcomes. Although GBM stem cells (GSC) are shown to play key roles in these processes, the molecular pathways governing the …
Rapid tumor growth, widespread brain-invasion, and therapeutic resistance critically contribute to glioblastoma (GBM) recurrence and …
Treatment Restrictions and the Risk of Death in Patients With Ischemic Stroke or Intracerebral Hemorrhage.
Reinink H, Konya B, Geurts M, Kappelle LJ, van der Worp HB. Reinink H, et al. Among authors: geurts m. Stroke. 2020 Sep;51(9):2683-2689. doi: 10.1161/STROKEAHA.120.029788. Epub 2020 Aug 6. Stroke. 2020. PMID: 32757755
BACKGROUND AND PURPOSE: Do-not-resuscitate (DNR) orders in the first 24 hours after intracerebral hemorrhage have been associated with an increased risk of early death. This relationship is less certain for ischemic stroke. We assessed the relation between treatment restri …
BACKGROUND AND PURPOSE: Do-not-resuscitate (DNR) orders in the first 24 hours after intracerebral hemorrhage have been associated with an in …
Epilepsy Associates with Decreased HIF-1alpha/STAT5b Signaling in Glioblastoma.
Berendsen S, Spliet WGM, Geurts M, Van Hecke W, Seute T, Snijders TJ, Bours V, Bell EH, Chakravarti A, Robe PA. Berendsen S, et al. Among authors: geurts m. Cancers (Basel). 2019 Jan 4;11(1):41. doi: 10.3390/cancers11010041. Cancers (Basel). 2019. PMID: 30621209 Free PMC article.
Epilepsy at presentation is an independent favorable prognostic factor in glioblastoma (GBM). In this study, we analyze the oncologic signaling pathways that associate with epilepsy in human GBMs, and that can underlie this prognostic effect. ...Hospital records were scree …
Epilepsy at presentation is an independent favorable prognostic factor in glioblastoma (GBM). In this study, we analyze the oncologic …
Therapeutic hypothermia and the risk of infection: a systematic review and meta-analysis.
Geurts M, Macleod MR, Kollmar R, Kremer PH, van der Worp HB. Geurts M, et al. Crit Care Med. 2014 Feb;42(2):231-42. doi: 10.1097/CCM.0b013e3182a276e8. Crit Care Med. 2014. PMID: 23989182 Review.
STUDY SELECTION: We included randomized controlled clinical trials of therapeutic hypothermia induced in adults for any indication, which reported the prevalence of infection in each treatment group. DATA EXTRACTION: For each study, we collected information about the basel …
STUDY SELECTION: We included randomized controlled clinical trials of therapeutic hypothermia induced in adults for any indication, which re …
On high-risk, low-grade glioma: What distinguishes high from low?
Geurts M, van den Bent MJ. Geurts M, et al. Cancer. 2019 Jan 15;125(2):174-176. doi: 10.1002/cncr.31834. Epub 2018 Dec 4. Cancer. 2019. PMID: 30512190 Free PMC article.
The distinction between high-risk and low-risk patients with low-grade glioma is far from clear. yet this criterion is used to select patients for immediate postsurgery radiotherapy and chemotherapy....
The distinction between high-risk and low-risk patients with low-grade glioma is far from clear. yet this criterion is used to select …
22 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page